View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Delphine Brault ... (+2)
  • Delphine Brault
  • Steven Boumans
Delphine Brault ... (+2)
  • Delphine Brault
  • Steven Boumans
 PRESS RELEASE

GENFIT : Résultats de l’Assemblée Générale Mixte du 17 juin 2025

GENFIT : Résultats de l’Assemblée Générale Mixte du 17 juin 2025 L’ensemble des projets de résolutions recommandés par le Conseil d’Administration a été approuvé (quorum : 27,21%). Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 17 juin 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui les résultats de son Assemblée Générale Mixte convoquée le 17 juin 2025. Le quorum réuni sur première convocation s’est é...

 PRESS RELEASE

GENFIT: June 17, 2025 Combined Shareholders Meeting Results

GENFIT: June 17, 2025 Combined Shareholders Meeting Results All resolutions recommended by the Board of Directors approved (quorum: 27.21%). Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27.21% and shareholders approved all of the resolutions, with...

Kaufman & Broad: 1 director

A director at Kaufman & Broad sold 15,000 shares at 33.700EUR and the significance rating of the trade was 88/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

Ahmed Ben Salem ... (+3)
  • Ahmed Ben Salem
  • Bruno Cavalier
  • Steven Boumans
FP TOTAL SE
TKA THYSSENKRUPP AG
EQNR EQUINOR ASA
MT ARCELORMITTAL SA
GALP GALP ENERGIA SGPS SA CLASS B
APAML APERAM SA
MC LVMH MOET HENNESSY LOUIS VUITTON SE
LI KLEPIERRE SA
COV COVIVIO SA
OUT1V OUTOKUMPU OYJ
GFC GECINA SA
SSAB A SSAB AB CLASS A
NXI NEXITY SA CLASS A
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
FLY SOCIETE FONCIERE LYONNAISE SA
GYC GRAND CITY PROPERTIES SA
TNG TRANSGENE SA
MERY MERCIALYS SA
EVN EVN AG
SZG SALZGITTER AG
EL ESSILORLUXOTTICA SA
WHA WERELDHAVE N.V.
KCO KLOECKNER & CO SE
BLND BRITISH LAND COMPANY PLC
BRBY BURBERRY GROUP PLC
KOF KAUFMAN & BROAD SA
JCQ JACQUET METALS SA
KER KERING SA
ALTA ALTAREA SCA
VNA VONOVIA SE
VOE VOESTALPINE AG
ACX ACERINOX SA
ENI ENI S.P.A.
XIOR XIOR STUDENT HOUSING N.V.
ERA ERAMET SA
ICAD ICADE SA
01913 PRADA S.P.A.
REP REPSOL SA
BYG BIG YELLOW GROUP PLC
COFB COFINIMMO SA
CAI CA IMMOBILIEN ANLAGEN AG
TEG TAG IMMOBILIEN AG
VASTB VASTNED RETAIL BELGIUM NV
PSPN PSP SWISS PROPERTY AG
UBS UBM DEVELOPMENT AG
SPSN SWISS PRIME SITE AG
PAT PATRIZIA AG
MONT MONTEA SCA
AED AEDIFICA SA
CARM CARMILA SAS
LEG LEG IMMOBILIEN AG
MONC MONCLER SPA
CPINV CARE PROPERTY INVEST SA
SAFE SAFESTORE HOLDINGS PLC
ARG ARGAN SA
VGP VGP NV
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
COL INMOBILIARIA COLONIAL SOCIMI SA
DIC DIC ASSET AG
MERLIN MERLIN PROPERTIES SOCIMI S.A.
DKG DEUTSCHE KONSUM REIT-AG
BP. BP P.L.C.
HOME NEINOR HOMES SA
AT1 AROUNDTOWN SA
LAND LAND SECURITIES GROUP PLC
MVC METROVACESA SA
NSI NSI N.V.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
INS INSTONE REAL ESTATE GROUP AG
AEDAS AEDAS HOMES SA
WDP WAREHOUSES DE PAUW SCA
ECMPA EUROCOMMERCIAL PROPERTIES NV
CTPNV CTP NV
SHEL SHELL PLC
ONE ONE UNITED PROPERTIES SA
TTS TRANSPORT TRADE SVCS
SHUR SHURGARD SELF STORAGE LIMITED
ATO ATOS SE
Ahmed Ben Salem ... (+3)
  • Ahmed Ben Salem
  • Bruno Cavalier
  • Steven Boumans
FP TOTAL SE
TKA THYSSENKRUPP AG
EQNR EQUINOR ASA
MT ARCELORMITTAL SA
GALP GALP ENERGIA SGPS SA CLASS B
APAML APERAM SA
MC LVMH MOET HENNESSY LOUIS VUITTON SE
LI KLEPIERRE SA
COV COVIVIO SA
ROG ROCHE HOLDING LTD
OUT1V OUTOKUMPU OYJ
GFC GECINA SA
SSAB A SSAB AB CLASS A
NXI NEXITY SA CLASS A
NOVN NOVARTIS AG
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
FLY SOCIETE FONCIERE LYONNAISE SA
GYC GRAND CITY PROPERTIES SA
MERY MERCIALYS SA
SZG SALZGITTER AG
EL ESSILORLUXOTTICA SA
WHA WERELDHAVE N.V.
KCO KLOECKNER & CO SE
BLND BRITISH LAND COMPANY PLC
BRBY BURBERRY GROUP PLC
KOF KAUFMAN & BROAD SA
JCQ JACQUET METALS SA
KER KERING SA
ALTA ALTAREA SCA
VNA VONOVIA SE
VOE VOESTALPINE AG
ACX ACERINOX SA
ENI ENI S.P.A.
XIOR XIOR STUDENT HOUSING N.V.
BAS BASF SE
SAN SANOFI
ICAD ICADE SA
01913 PRADA S.P.A.
REP REPSOL SA
BYG BIG YELLOW GROUP PLC
COFB COFINIMMO SA
CAI CA IMMOBILIEN ANLAGEN AG
TEG TAG IMMOBILIEN AG
VASTB VASTNED RETAIL BELGIUM NV
PSPN PSP SWISS PROPERTY AG
UBS UBM DEVELOPMENT AG
SPSN SWISS PRIME SITE AG
PAT PATRIZIA AG
MONT MONTEA SCA
AED AEDIFICA SA
CARM CARMILA SAS
LEG LEG IMMOBILIEN AG
MONC MONCLER SPA
CPINV CARE PROPERTY INVEST SA
SAFE SAFESTORE HOLDINGS PLC
ARG ARGAN SA
VGP VGP NV
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
COL INMOBILIARIA COLONIAL SOCIMI SA
DIC DIC ASSET AG
NN NN GROUP N.V.
MERLIN MERLIN PROPERTIES SOCIMI S.A.
DKG DEUTSCHE KONSUM REIT-AG
AZN ASTRAZENECA PLC
BP. BP P.L.C.
HOME NEINOR HOMES SA
AT1 AROUNDTOWN SA
LAND LAND SECURITIES GROUP PLC
MVC METROVACESA SA
NSI NSI N.V.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
INS INSTONE REAL ESTATE GROUP AG
AEDAS AEDAS HOMES SA
WDP WAREHOUSES DE PAUW SCA
DSY DASSAULT SYSTEMES SA
ECMPA EUROCOMMERCIAL PROPERTIES NV
CTPNV CTP NV
SHEL SHELL PLC
ONE ONE UNITED PROPERTIES SA
GSK GSK PLC
SHUR SHURGARD SELF STORAGE LIMITED
H2O HIDROELECTRICA S.A.
NOVO B NOVO NORDISK A/S
 PRESS RELEASE

GENFIT Reports First Quarter 2025 Financial Information

GENFIT Reports First Quarter 2025 Financial Information Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2025 and revenues for the first three months of 2025.1 Cash position As of March 31, 2025, the Company’s cash and cash equivalents amounted to €129.5 million compared with €74.0 million as of March 31, 2024, and €81.8 million a...

 PRESS RELEASE

GENFIT : Information financière du premier trimestre 2025

GENFIT : Information financière du premier trimestre 2025 Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 22 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui sa position de trésorerie au 31 mars 2025 et son chiffre d’affaires pour les trois premiers mois de 2025.1 Situation de Trésorerie  Au 31 mars 2025, la trésorerie et les équivalents de trésorerie de la Société s’élevaie...

 PRESS RELEASE

GENFIT va recevoir un paiement d’étape de 26,5 millions d’euros à la s...

GENFIT va recevoir un paiement d’étape de 26,5 millions d’euros à la suite de l’approbation du prix et du remboursement d’Iqirvo® par Ipsen en Italie Lille (France), Cambridge (Massachusetts, Etats-Unis), Zurich (Suisse), le 20 mai, 2025 – GENFIT (Nasdaq et Euronext : GNFT), société́ biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui qu’Iqirvo® d'Ipsen1 a obtenu l’approbation du prix et du remboursement en Italie pour le traitement de la cholangite biliaire ...

 PRESS RELEASE

GENFIT to receive a €26.5 million milestone payment following the appr...

GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that Ipsen’s Iqirvo®1 has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis (PBC). This major step unlocks a new milestone payment of €26.5 million under our Licensing...

 PRESS RELEASE

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fi...

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024) Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the publication of its 2025 Extra-Financial Performance Report (fiscal year 2024). Since 2022, GENFIT has published a detailed Extra-Financial Performance report in response to the growing interest of institutional and individual shareholders,...

 PRESS RELEASE

GENFIT : Publication du rapport de performance extra-financière 2025 (...

GENFIT : Publication du rapport de performance extra-financière 2025 (exercice 2024) Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 14 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui la publication de son rapport de performance extra-financière 2025 (exercice 2024).  Depuis 2022, GENFIT publie un rapport de performance extra-financière détaillé en réponse à l’intérêt croissant des actionnaires ins...

 PRESS RELEASE

GENFIT : Assemblée Générale Mixte du 17 juin 2025 — modalités de mise ...

GENFIT : Assemblée Générale Mixte du 17 juin 2025 — modalités de mise à disposition des documents préparatoires Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 7 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui la publication dans l’édition du Bulletin des Annonces Légales Obligatoires n° 55 du 7 mai 2025 de son avis de réunion valant convocation à l’Assemblée Générale Mixte qui se déroulera le 17 ju...

 PRESS RELEASE

GENFIT Annual Combined General Meeting of June 17, 2025 — Availability...

GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 7, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the May 7, 2025 French legal announcements bulletin n°55 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on June 17, 2025, at 10:00 am (CET), at...

 PRESS RELEASE

GENFIT to Present Latest ACLF Research at EASL Congress 2025

GENFIT to Present Latest ACLF Research at EASL Congress 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 5, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its participation at the European Association for the Study of the Liver (EASL) Annual Congress 2025 with six posters presenting the latest research in ACLF and multiple events highlighting the growing importance of ACLF within the hepatology community. I.      Poste...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch